Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Hepatosplenic T-Cell Lymphoma: A Population-Based Study Assessing Incidence and Association With Immune-Mediated Disease.

Montgomery M, van Santen MM, Biemond BJ, Diamond RH, Pals ST.

Gastroenterol Hepatol (N Y). 2015 Mar;11(3):160-3.

2.

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial.

Cornillie F, Hanauer SB, Diamond RH, Wang J, Tang KL, Xu Z, Rutgeerts P, Vermeire S.

Gut. 2014 Nov;63(11):1721-7. doi: 10.1136/gutjnl-2012-304094. Epub 2014 Jan 28.

3.

Drug therapies and the risk of malignancy in Crohn's disease: results from the TREATâ„¢ Registry.

Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Langholff W, Londhe A, Sandborn WJ.

Am J Gastroenterol. 2014 Feb;109(2):212-23. doi: 10.1038/ajg.2013.441. Epub 2014 Jan 7.

PMID:
24394749
4.

Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.

Ferrante M, Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens GR, van der Woude CJ, Danese S, Diamond RH, Oortwijn AF, Tang KL, Miller M, Cornillie F, Rutgeerts PJ; International Organization for the Study of Inflammatory Bowel Diseases.

Gastroenterology. 2013 Nov;145(5):978-986.e5. doi: 10.1053/j.gastro.2013.08.010. Epub 2013 Aug 14.

PMID:
23954314
5.

Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREATâ„¢ registry.

Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A, Sandborn WJ.

Am J Gastroenterol. 2012 Sep;107(9):1409-22. doi: 10.1038/ajg.2012.218. Epub 2012 Aug 14.

6.

A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease.

Lichtenstein GR, Rutgeerts P, Sandborn WJ, Sands BE, Diamond RH, Blank M, Montello J, Tang L, Cornillie F, Colombel JF.

Am J Gastroenterol. 2012 Jul;107(7):1051-63. doi: 10.1038/ajg.2012.89. Epub 2012 May 22.

7.

On the updated ECCO consensus guidelines for medical management of Crohn's disease.

Esser D, Cornillie F, Diamond RH, Spiegel RJ.

J Crohns Colitis. 2011 Apr;5(2):165-6. doi: 10.1016/j.crohns.2010.02.002. Epub 2010 Feb 12. No abstract available.

PMID:
21453888
8.

Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality.

Kotlyar DS, Blonski W, Diamond RH, Wasik M, Lichtenstein GR.

Am J Gastroenterol. 2010 Oct;105(10):2299-301. doi: 10.1038/ajg.2010.213. Review. No abstract available.

PMID:
20927075
9.

A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.

Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, Sampat S, Mendizabal M, Lin MV, Lichtenstein GR.

Clin Gastroenterol Hepatol. 2011 Jan;9(1):36-41.e1. doi: 10.1016/j.cgh.2010.09.016. Epub 2010 Oct 1. Review.

PMID:
20888436
10.

Infliximab, azathioprine, or combination therapy for Crohn's disease.

Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group.

N Engl J Med. 2010 Apr 15;362(15):1383-95. doi: 10.1056/NEJMoa0904492.

11.

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.

Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, Johanns J, Lang Y, Sandborn WJ.

Aliment Pharmacol Ther. 2009 Aug;30(3):210-26. doi: 10.1111/j.1365-2036.2009.04027.x. Epub 2009 Apr 21.

12.

A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistency.

Keshavarzian A, Mayer L, Salzberg B, Garone M, Finkelstein W, Cappa J, Brand M, Hain J, Zelinger D, Hegedus R, Diamond RH, Campbell U, Lane C, Stang P, Watson J, Cominelli F.

Gastroenterol Hepatol (N Y). 2007 May;3(5):381-90.

13.

Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis.

Lichtenstein GR, Cohen R, Yamashita B, Diamond RH.

J Clin Gastroenterol. 2006 Sep;40(8):669-77. Review.

PMID:
16940876
14.

Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ.

Clin Gastroenterol Hepatol. 2006 May;4(5):621-30. Erratum in: Clin Gastroenterol Hepatol. 2006 Jul;4(7):931.

PMID:
16678077
15.

Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study.

Sands BE, Blank MA, Diamond RH, Barrett JP, Van Deventer SJ.

Aliment Pharmacol Ther. 2006 Apr 15;23(8):1127-36.

16.

Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.

Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ.

Am J Gastroenterol. 2006 May;101(5):1030-8.

PMID:
16606351
17.

Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.

Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB.

Gastrointest Endosc. 2006 Mar;63(3):433-42; quiz 464.

PMID:
16500392
18.

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W, Rutgeerts P.

Clin Gastroenterol Hepatol. 2004 Jul;2(7):542-53.

PMID:
15224278
19.

ATF-7, a novel bZIP protein, interacts with the PRL-1 protein-tyrosine phosphatase.

Peters CS, Liang X, Li S, Kannan S, Peng Y, Taub R, Diamond RH.

J Biol Chem. 2001 Apr 27;276(17):13718-26. Epub 2001 Jan 22.

20.

PRL-1 PTPase expression is developmentally regulated with tissue-specific patterns in epithelial tissues.

Kong W, Swain GP, Li S, Diamond RH.

Am J Physiol Gastrointest Liver Physiol. 2000 Sep;279(3):G613-21.

21.

Expression of the protein tyrosine phosphatase, phosphatase of regenerating liver 1, in the outer segments of primate cone photoreceptors.

Yarovinsky TO, Rickman DW, Diamond RH, Taub R, Hageman GS, Bowes Rickman C.

Brain Res Mol Brain Res. 2000 Apr 14;77(1):95-103.

PMID:
10814835
22.

Hepatic failure in a patient taking rosiglitazone.

Forman LM, Simmons DA, Diamond RH.

Ann Intern Med. 2000 Jan 18;132(2):118-21.

PMID:
10644272
23.
24.
25.

Expression of PRL-1 nuclear PTPase is associated with proliferation in liver but with differentiation in intestine.

Diamond RH, Peters C, Jung SP, Greenbaum LE, Haber BA, Silberg DG, Traber PG, Taub R.

Am J Physiol. 1996 Jul;271(1 Pt 1):G121-9.

PMID:
8760115
26.

Rapid activation of the Stat3 transcription complex in liver regeneration.

Cressman DE, Diamond RH, Taub R.

Hepatology. 1995 May;21(5):1443-9.

PMID:
7737651
27.

PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth.

Diamond RH, Cressman DE, Laz TM, Abrams CS, Taub R.

Mol Cell Biol. 1994 Jun;14(6):3752-62.

28.

Novel delayed-early and highly insulin-induced growth response genes. Identification of HRS, a potential regulator of alternative pre-mRNA splicing.

Diamond RH, Du K, Lee VM, Mohn KL, Haber BA, Tewari DS, Taub R.

J Biol Chem. 1993 Jul 15;268(20):15185-92.

29.

Small intestinal growth caused by feeding red kidney bean phytohemagglutinin lectin to rats.

Banwell JG, Howard R, Kabir I, Adrian TE, Diamond RH, Abramowsky C.

Gastroenterology. 1993 Jun;104(6):1669-77.

PMID:
8500725
30.
31.

The role of cimetidine-enhanced technetium-99m-pertechnetate imaging for visualizing Meckel's diverticulum.

Diamond RH, Rothstein RD, Alavi A.

J Nucl Med. 1991 Jul;32(7):1422-4. No abstract available.

Supplemental Content

Loading ...
Support Center